Form 4: Rapport Therapeutics COO Granted 132,000 Stock Options

Rapport Therapeutics' Chief Operating Officer, Cheryl Gault, was granted 132,000 stock options with an exercise price of $27.75.

Summary

• Cheryl Gault, Chief Operating Officer of Rapport Therapeutics, Inc. (RAPP), was granted 132,000 stock options.
• The options have an exercise price of $27.75 per share.
• The grant date for these options was February 2, 2026.
• The options will vest in forty-eight equal monthly installments following January 1, 2026, contingent on Ms. Gault's continued service.
• The expiration date for these stock options is February 2, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management incentives with shareholder interests, without indicating any significant new operational or financial developments.

Positives

• The grant of stock options aligns the Chief Operating Officer's long-term interests with those of shareholders, incentivizing performance and retention.
• Equity compensation is a standard practice for attracting and retaining key executive talent in the biotechnology sector.

Future Outlook

The vesting schedule, which extends over 48 months following January 1, 2026, indicates an expectation of continued service from the Chief Operating Officer, aligning her incentives with the company's long-term performance.

Industry Context

StockSavvy.ai notes that the grant of stock options to key executives like a Chief Operating Officer is a standard and widely adopted practice within the biotechnology and pharmaceutical industries. This form of compensation is crucial for attracting, retaining, and motivating top talent, aligning their financial interests with the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• The grant of stock options as a component of executive compensation is a common practice across the biotech industry, comparable to compensation structures at companies like Moderna, BioNTech, or Regeneron, which frequently use equity to incentivize leadership.
• The 48-month vesting schedule is typical for executive equity grants, designed to promote long-term commitment and performance, similar to vesting periods observed in many S&P 500 companies' executive compensation plans.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options aims to align the Chief Operating Officer's financial incentives with shareholder value creation, potentially leading to improved long-term performance.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, which can positively impact employee morale and retention.

Next Steps

• The stock options will vest in 48 equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service.

Key Dates

Recommendation

The filing reports a routine stock option grant to a key executive, which is a standard compensation practice and does not provide new information warranting a change in investment recommendation. Investors should consider broader company fundamentals and market conditions.

Keywords

Rapport Therapeutics, RAPP, Stock Option, Cheryl Gault, Form 4, Insider Transaction, Executive Compensation, Equity Grant